Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
Status: | Recruiting |
---|---|
Conditions: | Anemia |
Therapuetic Areas: | Hematology |
Healthy: | No |
Age Range: | Any - 70 |
Updated: | 9/27/2018 |
Start Date: | January 2015 |
End Date: | July 2024 |
Contact: | Timothy Krepski |
Email: | tkrepsk1@fairview.org |
Phone: | 612-273-2800 |
Fludarabine-based preparative regimen followed by an allogeneic hematopoietic stem cell
transplant using related or unrelated donor in persons 0-70 years of age diagnosed with
dyskeratosis congenita or severe aplastic anemia who have bone marrow failure characterized
by a requirement for red blood cell and platelet transfusions. Three different preparative
regimens are included based on disease and donor type.
transplant using related or unrelated donor in persons 0-70 years of age diagnosed with
dyskeratosis congenita or severe aplastic anemia who have bone marrow failure characterized
by a requirement for red blood cell and platelet transfusions. Three different preparative
regimens are included based on disease and donor type.
Inclusion Criteria:
- Aged 0 - 70 years
- Acceptable hematopoeitic stem cell donor
- Dyskeratosis Congenita (DC) with evidence of BM failure defined as:
- requirement for red blood cell and/or platelet transfusions or
- requirement for G-CSF or GM-CSF or erythropoietin or
- refractory cytopenias having one of the following three
- platelets <50,000/uL or transfusion dependent
- absolute neutrophil count <500/uL without hematopoietic growth factor
support
- hemoglobin <9g/uL or transfusion dependent
- Diagnosis of DC with a triad of mucocutaneous features:
- oral leukoplakia
- nail dystrophy
- abnormal reticular skin hyperpigmentation, or
- Diagnosis of DC with one of the following:
- short telomeres (under a research study)
- mutation in telomerase holoenzyme (DKC1, TERT, TERC, NOP10, NHP2, TCAB1)
- mutation in shelterin complex (TINF2)
- mutation in telomere-capping complex (CTC1)
- Severe Aplastic Anemia (SAA) primary transplant with evidence of BM failure:
- Refractory cytopenia defined by bone marrow cellularity <50% (with < 30% residual
hematopoietic cells)
- Diagnosis of SAA with refractory cytopenias having one of the following three:
- platelets <20,000/uL or transfusion dependent
- absolute neutrophil count <500/uL without hematopoietic growth factor support
- absolute reticulocyte count <20,000/uL
- Severe Aplastic Anemia (SAA) requiring a 2nd transplant
- Graft failure as defined by blood/marrow chimerism of < 5%
- Early myelodysplastic features
- With or without clonal cytogenetic abnormalities
- Adequate organ function defined as:
- cardiac: left ventricular ejection fraction ≥ 35% with no evidence of
decompensated heart failure
- pulmonary: DLCO ≥30% predicted, no supplemental oxygen requirement
- renal: Glomerular filtration rate (GFR) ≥30% predicted
- Voluntary written consent
Exclusion Criteria:
- Acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on
biopsy
- Pregnant or lactating
- Uncontrolled infection
- Prior radiation therapy (applies to SAA patients only)
- Diagnosis of Fanconi anemia based on DEB
- Diagnosis of dyskeratosis congenita with advanced MDS or acute myeloid leukemia with
>30% blasts
We found this trial at
1
site
2450 Riverside Ave
Minneapolis, Minnesota 55454
Minneapolis, Minnesota 55454
(612) 273-3000
Principal Investigator: Jakub Tolar, MD
Phone: 612-273-2800
University of Minnesota Medical Center, Fairview Improving patients' lives drives the innovation that makes University...
Click here to add this to my saved trials